CAMBRIDGE, Mass., April 10, 2012 – OvaScience™, a fertility company focused on the discovery, development and commercialization of novel treatments for infertility, announced today that the company will present at the 2012 Boston Biotech Business Development Conference, being held April 17-18 at Tthe Mandarin Oriental Hotel in Boston. As part of the conference, the company will participate in a Fertility Summit on April 178 at 10 a.m. with OvaScience scientific advisory board members Robert Casper, M.D., F.R.C.S.C., Alan Penzias, M.D., Mitchell Rosen, M.D., David Sable, M.D., David Sinclair, Ph.D., and Jonathan Tilly, Ph.D., along with patient advocates in the field of infertility.
OvaScience is a privately-held fertility company focused on the discovery, development and commercialization of novel treatments for infertility. OvaScience is working to improve the treatment of female infertility based on patented technology exclusively licensed from Massachusetts General Hospital. The company's team of scientists, physicians and advisers are recognized leaders in the field of reproductive medicine. For more information, please visit the company’s website at www.ovascience.com.